Company news

Pharming Group NV news in 2026

Pharming Group NV's news releases, calls and decks from 2026, newest first.

View company

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

October 27, 2026

Pharming Group announces third quarter 2026 revenues above market expectations

October 22, 2026

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

October 14, 2026

Pharming announces CEO transition

September 29, 2026

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

September 25, 2026

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

September 22, 2026

FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.

September 14, 2026

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

September 11, 2026

Pharming Group to participate in September investor conferences

September 9, 2026

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

August 13, 2026

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

August 4, 2026

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

July 30, 2026

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

July 16, 2026

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja to treat children aged 4 to 11 years with APDS

June 5, 2026

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

June 4, 2026

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

June 2, 2026

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

May 28, 2026

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

May 22, 2026

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

May 7, 2026

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

May 7, 2026

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

April 23, 2026

Pharming Group announces the 2026 Annual General Meeting of Shareholders

April 16, 2026

Pharming Group to participate in April investor conferences

April 7, 2026

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

April 2, 2026

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

March 27, 2026

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

March 24, 2026

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

March 12, 2026

Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

February 26, 2026

Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day

February 3, 2026

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

February 1, 2026

Pharming Group reports preliminary 2025 revenues and announces Investor Day

January 8, 2026

Calls in 2026

Decks in 2026